New technologies have enabled scientists to obtain enhanced insights on processes taking place at subcellular levels. Laser capture microdissection (LCM) is observed as a key technique that can precisely collect homogenous cells, becoming an efficient method for capturing pure cell populations in molecular studies. According to Persistence Market Research, the increasing influence of molecular analyses and cell biologics on the dynamics of life sciences & healthcare industry will promote the adoption of laser capture microdissection techniques, especially in cancer research studies. The report on global laser capture microdissection market offers a five-year forecast, anticipating the market to reach US$ 143 million value by the end of 2022. During the forecast period, 2017-2022, the global market for laser capture microdissection is assessed to expand at a robust CAGR, particularly due to effective applications of laser capture microdissection in field of proteomics and genomics.
Higher Demand for a Combination of Infrared LCM & Ultraviolet LCM
LCM systems are primarily characterized by the type of laser diode equipped in them. In infrared (IR) LCM systems, the thermoplastic film is impregnated with a dye that absorbs light energy in the near-IR spectrum, preventing the cellular constituents from incurring damage. Ultraviolet (UV) laser capture microdissections work on a different principle, wherein the narrow-beam UV laser keeps the desired cell population undamaged, and draws only the required cells while concurrently extirpating the unwanted tissues.
In 2017, nearly half of the revenues procured in the global laser capture microdissection market are anticipated to be accounted by UV-based LCM systems. Meanwhile, IR laser capture microdissection systems are anticipated to register a relatively speedy growth in revenues over the forecast period. Laser capture microdissection systems developed with the combination of IR and UV laser diodes are anticipated to register fastest growth in terms of demand, and will reflect a 10.9% CAGR during the forecast period. By the end of 2022, the global laser capture microdissection market will also incur an estimated US$ 11 million revenues from the sales of immunofluorescence LCM systems.
Get Sample Copy Of This @ https://www.persistencemarketresearch.com/samples/18598
Academic Institutes to Account for Largest Revenue Share as End-users
Cancer research studies are observed to be the key applications of laser capture microdissection techniques as they aid the studies on molecular progression of cancer cells and tissues. Academic institutes are actively adopting LCM systems, and using these methods in identification of genetic differences between cancer tissues, preneoplastic tissues and normal tissues in the same patient. In 2017, LCM systems being sold to academic institutes are anticipated to rake in over US$ 50 million revenues, translating into more than half of global revenues estimated in the report.
Hospitals and pharmaceuticals & biotech companies are also anticipated to emerge as key end-users of laser capture microdissection. The report further projects that North America will a leading region in terms of end-use of laser capture microdissection across academic institutes, pharmaceutical & biotech companies, as well as hospitals. In the near future, companies and research institutes are likely to collaborate towards increasing the application purview of laser capture microdissection, particularly in diagnostics.
Future Prospects of Manufacturing LCM Systems
Currently, several players in the global laser capture microdissection market are anticipated to focus on developing LCM systems towards their effective applications, which include biomarker discovery and cancer chemoprevention. Some companies are also likely to enhance LCM systems equipped with immunofluorescence laser diodes. The global laser capture microdissection market is niche in terms of its size, compared to other biotechnology markets. In the near future, the global market for laser capture microdissection will continue to witness active participation of a handful of companies, which include Thermo Fisher Scientific Inc., Danaher Corporation, Carl Zeiss AG, Molecular Machines & Industries, Theranostics Health Inc., Ocimum Biosolutions LLC, 3DHISTECH Ltd., and AvanSci Bio LLC.